Raajit K. Rampal, MD, PhD
While JAK inhibitors have become a staple in treatment for select patients with polycythemia vera (PV) and myelofibrosis, further clinical trial efforts are needed for when patients fail on or are intolerant of this class of agents, explained Raajit K. Rampal, MD, PhD.
“There are a number of really interesting trials ongoing right now,” said Rampal, a hematologic oncologist at Memorial Sloan Kettering Cancer. “The landscape will eventually tell us which one is the most promising agent.”
... to read the full story